Sheridan Capital Raises Nearly $1.35B Across Two Healthcare Funds
Sheridan Capital Partners closed a $1.1 billion Fund IV and a separate $245 million debut healthcare IT fund. The aggregate is nearly $1.35 billion across two private-equity vehicles—not one fund.
Sheridan Capital Partners has raised nearly $1.35 billion across two separate healthcare private-equity vehicles: a $1.1 billion fourth flagship fund and a $245 million debut fund dedicated to healthcare information technology.
The distinction matters. Sheridan did not close one $1.35 billion fund, and these are private-equity vehicles rather than early-stage venture funds.
Two funds, two mandates
| Vehicle | Size | Status | Strategy |
|---|---|---|---|
| Sheridan Capital Partners Fund IV | $1.1 billion | Final close at hard cap | Founder-owned lower-middle-market healthcare businesses |
| Sheridan Healthcare IT Fund I | $245 million | Final close, reported | Smaller healthcare software and technology businesses |
Fund IV exceeded its $800 million target and reached its hard cap in about 60 days. Sheridan's previous flagship closed at $575 million in 2023.
The healthcare IT vehicle's $245 million size was reported by The Wall Street Journal. Sheridan's public announcement independently confirms Fund IV but does not present the IT vehicle's full terms.
Fund IV moves Sheridan further up-market
Sheridan plans to target North American healthcare companies with approximately $5 million to $25 million of EBITDA and build a portfolio of roughly 12 businesses.
At $1.1 billion, Fund IV has substantially more capacity than its predecessor. That can support larger initial checks and follow-on acquisitions, but it may also require Sheridan to compete with bigger sponsors for assets.
Healthcare services can offer durable demand, fragmented markets and recurring reimbursement. They also bring risks that software investors can underestimate: reimbursement changes, clinical quality, staffing constraints, regulatory exposure and leverage.
The dedicated healthcare IT vehicle
Sheridan reportedly expects the $245 million technology fund to back six to eight companies. Existing investments include Cadara, ICANotes and PtEverywhere.
Separating healthcare IT from the flagship creates clearer portfolio construction and allows smaller software deals that may not fit Fund IV. It also exposes LPs directly to AI-related disruption. Clinical software can gain value through automation, but incumbent products can lose pricing power if new tools reduce switching costs or compress feature differentiation.
What the fundraising says
Fund IV reached its hard cap quickly despite a difficult environment for many private-market managers. Sheridan could point to recent exits and a specialist healthcare track record.
Arkansas Teacher Retirement System reportedly committed up to $45 million to Fund IV. Sheridan did not disclose a complete LP list, fee terms, carried interest, fund-level leverage or performance metrics.
The closing announcement therefore demonstrates fundraising demand, not realized investment performance.
Risks and unanswered questions
- Deployment pressure: a fund nearly twice the size of its predecessor needs a larger opportunity set.
- Healthcare regulation: reimbursement and compliance changes can alter earnings quickly.
- Buy-and-build execution: add-on acquisitions create integration and leverage risk.
- Technology disruption: the IT fund must distinguish durable workflow infrastructure from features that AI vendors can reproduce.
- Performance opacity: no net IRR, TVPI, DPI or loss ratio was disclosed.
Editorial view
The strongest signal is Sheridan's ability to raise two vehicles with distinct mandates at the same time. Fund IV expands the core healthcare buyout strategy, while the IT fund creates a focused route into smaller software assets.
The correct headline number is nearly $1.35 billion across two funds. Treating it as a single fund would obscure both the investment mandates and the different evidentiary basis for each close.
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.
